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RESEARCH ARTICLE
Chromokinesin KIF4A teams up with stathmin 1 to regulate
abscission in a SUMO-dependent manner
Sabine A. G. Cuijpers1,*, Edwin Willemstein1, Jan G. Ruppert2,‡, Daphne M. van Elsland1,
William C. Earnshaw2 and Alfred C. O. Vertegaal1,§
ABSTRACT
Cell division ends when two daughter cells physically separate via
abscission, the cleavage of the intercellular bridge. It is not clear how
the anti-parallel microtubule bundles bridging daughter cells are
severed. Here, we present a novel abscission mechanism. We
identified chromokinesin KIF4A, which is adjacent to the midbody
during cytokinesis, as being required for efficient abscission. KIF4A is
regulated by post-translational modifications. We evaluated
modification of KIF4A by the ubiquitin-like protein SUMO. We
mapped lysine 460 in KIF4A as the SUMO acceptor site and
employed CRISPR-Cas9-mediated genome editing to block SUMO
conjugation of endogenous KIF4A. Failure to SUMOylate this site in
KIF4A delayed cytokinesis. SUMOylation of KIF4A enhanced the
affinity for the microtubule destabilizer stathmin 1 (STMN1). We here
present a new level of abscission regulation through the dynamic
interactions between KIF4A and STMN1 as controlled by SUMO
modification of KIF4A.
KEY WORDS: Mitosis, Abscission, Cytokinesis, KIF4A,
Post-translational modification, SUMO, Stathmin 1
INTRODUCTION
Abscission is the final step of cell division in which the two
daughter cells are separated to start their own independent life. Our
present understanding of abscission is limited (Mierzwa and
Gerlich, 2014). Prior to abscission, the cleavage furrow is formed
involving key players, like actin, myosin, septin and anillin,
culminating in the formation of the constricted intercellular bridge
(Field and Alberts, 1995; Joo et al., 2007; Lewellyn et al., 2011;
Mabuchi, 1994; Mavrakis et al., 2014; Mullins and Biesele, 1977;
Nunnally et al., 1980; Reichl et al., 2008; Sanger et al., 1994;
Schroeder, 1968; Uehara et al., 2010; Zhou and Wang, 2008).
Subsequently, the cortex of the intercellular bridge is narrowed to a
single stalk of 17-nm-diameter filaments (Guizetti et al., 2011). This
process involves the ESCRT-III complex and spastin-mediated
microtubule (MT) disassembly (Connell et al., 2009; Yang et al.,
2008). Although spastin knockdown results in a delay in MT
disassembly, the process is not abolished, indicating the existence of
additional abscission pathway components.
Post-translational modifications play a major role in mitotic
regulation. Important modifications include phosphorylation and
modification by small proteins including ubiquitin and small
ubiquitin-like modifier (SUMO) (Barr et al., 2004; Cubeñas-Potts
et al., 2015; Dasso, 2008; Deribe et al., 2010; Eifler and Vertegaal,
2015; Flotho and Melchior, 2013; Gareau and Lima, 2010; Glotzer
et al., 1991; Gurley et al., 1973; King et al., 1994, 1996; Li and
Hochstrasser, 1999; Peters, 2002; Ribet et al., 2017; Pohl and
Jentsch, 2008; Seeler and Dejean, 2017; Seufert et al., 1995;
Teixeira and Reed, 2013; Zhang et al., 2008). Inactivating SUMO
conjugation machinery components indeed delays cell cycle
progression and results in chromosomal aberrations (Hayashi
et al., 2002; He et al., 2015; Nacerddine et al., 2005; Schimmel
et al., 2014), but it is unclear how. SUMO (herein referring to
mammalian SUMO1–SUMO3) is conjugated to hundreds of
substrates (Hendriks et al., 2014; Hendriks and Vertegaal, 2016a;
Schimmel et al., 2014), but little is known about the impact of
SUMO on key substrates in mitosis. What is observed is that SUMO
accumulates at the midbody during cytokinesis, but – again – its
functional relevance nor the relevant substrates for cytokinesis are
unclear (Fu et al., 2005; Nie and Boddy, 2016; Pelisch et al., 2017).
One protein critical for cytokinesis is the chromokinesin KIF4A,
which is preferentially localized at the midbody, where it is
important for PRC1 recruitment and for MT organization at the
midbody (Hu et al., 2011; Kurasawa et al., 2004; Lee and Kim,
2004; Zhu and Jiang, 2005; Zhu et al., 2006). Here, we identified
KIF4A as a SUMOylated protein and show that this modification is
important for dynamic interaction with the MT destabilizer stathmin
1 (STMN1). SUMOylation thus has a role in cytokinesis.
RESULTS
The human chromokinesin KIF4A is modified by one SUMO
moiety
We aimed to understand the mechanisms and effects of
SUMOylation of the chromokinesin KIF4A (Cubeñas-Potts et al.,
2015; Kurasawa et al., 2004) to obtain more detailed understanding
of how SUMO regulates this important process of mitosis (Fig. 1A).
KIF4A has been identified as SUMO target protein in at least ten
individual SUMOylation proteomics studies, indicating that this
protein is one of the top targets for SUMO (Hendriks et al., 2014;
Hendriks and Vertegaal, 2016a; Schimmel et al., 2014).
Immunoblot analysis confirmed KIF4A as a SUMO target. To
enrich for SUMOylated proteins, U2OS cell lines either stably
expressing His10–SUMO2 or not at close to endogenous levels were
lysed and a His10 pulldown was performed. Immunoblot analysis
revealed modification of endogenous KIF4A by one single SUMO
moiety (Fig. 1B). This was confirmed by transfecting U2OS cells
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with either control or HA–KIF4A constructs. After enrichment for
KIF4A by HA immunoprecipitation (IP), under conditions where
SUMOylation is preserved, immunoblotting against SUMO2/3
confirmed modification of HA–KIF4A by endogenous SUMO2/3
(Fig. 1C). Additionally, HA–KIF4A enriched in a non-denaturing
manner was able to be SUMOylated in vitro upon addition of
SUMO E1 (SAE1/2), SUMO E2 (UBC9) and SUMO2 (Fig. 1D).
While KIF4A was efficiently modified by SUMO under in vitro
conditions, the level of SUMOylation was considerably lower in
tissue culture cells as the SUMOylated fraction of KIF4A could not be
observed by staining for bulk KIF4A in input samples. The
modification might be specific for a certain cell cycle phase or for a
functionally distinct fraction of KIF4A. However, no clear dynamic
SUMOylation levels for KIF4A were observed throughout the cell
cycle (Fig. S1) or duringmitosis (Fig. S2). This suggests that either the
timewindow duringwhich the fraction of SUMOylatedKIF4A shows
dynamics is too small to resolve using this experimental set-up, or that
a specific fraction of SUMOylated KIF4A is continuously present.
KIF4A is SUMOylated on lysine 460 in a SIM-dependent
manner
Modification by one single SUMO2 moiety indicates targeting of a
particular lysine residue in KIF4A. Various lysine-to-arginine
KIF4A mutants were made to localize the SUMO acceptor lysine in
KIF4A and transfected into U2OS cell lines without or with stable
expression of His10–SUMO2. Mutating lysine 460 to arginine
(K460R) abolished HA–KIF4A SUMOylation (Fig. 2A). The
SUMO E2 UBC9 reportedly recognizes the consensus
SUMOylation motif KxE in target proteins (Bernier-Villamor
et al., 2002). Although KIF4A lysine 460 is not located in this
specific motif, two adjacent glutamic acid residues could be part of
either an inverted consensus motif ExK (Matic et al., 2010) or a less
common KE motif (Pichler et al., 2005). While the single motif
mutations did not abolish HA–KIF4A SUMOylation, replacing
both glutamic acid residues simultaneously did, suggesting that
both motifs can be utilized by the SUMO conjugation machinery in
cells in a redundant manner.
Fig. 1. The human chromokinesin KIF4A is modified by a single SUMO moiety. (A) Chromokinesin KIF4A is required for the positioning of mitotic
chromosomes and stabilization of the bipolar spindle. In cytokinesis, KIF4A localizes at the intercellular bridge. The post-translational modifier SUMO is
required for mitosis, and is conjugated to KIF4A. In this project, we investigate the functional role of KIF4A SUMOylation. (B) U2OS cells without or with stable
expression of His10–SUMO2 were lysed. A His10 pulldown was performed to enrich for SUMOylated proteins. Input and pulldown samples were analyzed by
immunoblotting using antibodies against KIF4A and SUMO2/3. (C) U2OS cells were transfected with a control or HA–KIF4AWT construct and lysed after 3 days.
An HA IP was performed to enrich HA-KIF4AWT. Input and IP samples were analyzed by immunoblotting using antibodies against SUMO2/3 or the HA tag.
(D) U2OS cells were transfected with a construct encoding HA–KIF4AWT, lysed after 3 days and an HA IP was performed. The purified HA-KIF4AWT was
in vitro SUMOylated by the addition of SUMO E1 and SUMO E2, and either incubated at 4°C for 3 h with the indicated concentrations of SUMO2 (left) or for
the indicated time with 220 ng/µl SUMO2 (right). Samples were analyzed by immunoblotting using an antibody against the HA-tag. The experimental
procedures for B–D are summarized in the cartoons on the right. Each experiment was performed at least three times.
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To verify these results, an in vitro SUMOylation assay was
performed on purified wild-type (WT) HA–KIF4A and mutant
HA–KIF4A proteins. While WT HA-KIF4A was SUMOylated
upon addition of SUMO2, both the K460R and E458A/E461A
mutants were not, confirming the results obtained from cells
(Fig. 2B). However, unlike our observation in cells, mutating the
inverted consensus motif was sufficient to abolish KIF4A
SUMOylation in vitro. The in vitro assay only contained SUMO
E1 and SUMO E2 enzymes. However, cells express various SUMO
E3 proteins that can contribute to the specific modification of
KIF4A. Therefore, our experiments suggest that KIF4A
SUMOylation occurs via two complementary mechanisms either
through direct recognition of the inverted consensus motif by UBC9
or supported by a SUMO E3 to recognize the KE motif.
Interestingly, in-depth analysis of the sequence of KIF4A also
revealed a potential SUMO interaction motif (SIM) at amino acids
(aa) 148–152, located within the motor domain of this kinesin
family member. To determine whether the SIM influences
SUMOylation of KIF4A, this motif was separately mutated from
ILDLL to AADAA to keep the hydrophobic nature of the amino
acids, but to prevent SUMO interaction according to common
practice in the SUMO field (Song et al., 2004). U2OS cells either
stably expressing His10–SUMO2 or not were transfected with WT
or mutant HA–KIF4A plasmids. Upon His10 pulldown and
immunoblot analysis, the SIM mutation was observed to abolish
SUMOylation of each of these three HA–KIF4A constructs
(Fig. 2C). Thus, KIF4A SUMOylation requires this SIM.
Therefore, we propose that a SUMO–UBC9 complex is able to
bind the SIM in KIF4A, which brings the SUMO E2 in close
proximity to lysine 460 to either directly recognize the inverted
consensus motif or SUMOylate KIF4A with the help of a SUMO
E3 (Fig. 2D).
Fig. 2. KIF4A is SUMOylated on lysine 460 in a SIM-dependent manner. (A) U2OS cells without or with stable expression of His10–SUMO2 were transfected
with a control, HA–KIF4AWT or indicated mutant construct and lysed after 3 days. A His10 pulldown was performed to enrich for SUMOylated proteins. The
samples were analyzed by immunoblotting using antibodies against the HA tag and SUMO2/3, while equal loading was confirmed by Ponceau S staining.
(B) U2OS cells were transfected with plasmids encoding HA–KIF4AWT or the indicated mutants, lysed after 3 days, and the HA-tagged proteins were
enriched by IP. An in vitro SUMOylation assay was performed by the addition of SUMO E1 and SUMO E2, followed by incubation for 3 h at 4°C in the presence
of 220 ng/µl SUMO2. Samples were analyzed by immunoblotting using an antibody against the HA tag. (C) U2OS cells without or with stable expression of
His10–SUMO2 were transfected with control plasmid, or plasmids encoding HA–KIF4AWT, HA–KIF4A E458A or HA–KIF4A E461A that either did not or did
contain additional mutations to abolish theSUMO interactionmotif (SIM ILDLLmutated to AADAA). After 3 days, cells were lysed. Upon enrichment for SUMOylated
proteins by His10 pulldown, samples were analyzed by immunoblotting with antibodies against the HA tag or SUMO2/3, and by Ponceau S staining to confirm equal
loading. Each experiment was performed at least three times. (D) A cartoon depicting the proposed mechanism of KIF4A SUMOylation in human cells. The
SUMO E2 (UBC9)–SUMO complex interacts with the KIF4A dimer via the SIM in its head domain. Subsequently, UBC9 is able to covalently attach SUMO to
lysine 460 in the stalk domain, either directly through the inverted consensus motif (ExK) or with the help of a SUMO E3 ligase through the second motif (KE).
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Does SUMO modification affect the activity of the motor protein
KIF4A? We performed an ATPase activity assay to follow KIF4A
activity in the absence and presence of modification by SUMO2.
Recombinant GST–KIF4A WT or its SUMOylation-deficient
mutants (K460R and E458A/E461A) were incubated with
SUMOylation mix in the absence or presence of SUMO2 to
generate KIF4A proteins either modified or not by SUMO2.
ATPase activity assays were performed in the absence or presence of
MTs, since MT binding is required for specific KIF4A ATPase
activity as required for motor activity (Nunes Bastos et al., 2013).
GST–KIF4AWTwas active in the presence ofMTs as expected, but
SUMOylation did not affect the ATPase activity of KIF4A
(Fig. 3A). Aliquots of the samples were analyzed by
immunoblotting to confirm in vitro SUMOylation (Fig. 3B). This
suggests that both KIF4A mutants are functional for MT binding
and dimerization, since both are essential for ATPase activity, and
SUMO modification is not critical for KIF4A motor activity.
Mutating lysine 460 in endogenousKIF4Avia genomeediting
by CRISPR-Cas9 abolishes SUMOylation
We next studied the role of KIF4A SUMOylation in vivo by genetic
manipulation in U2OS cells. CRISPR-Cas9-directed genome
editing was used in combination with a repair template to mutate
the endogenous KIF4A gene to yield the K460Rmutant. Each clone
was tested by PCR and digestion with restriction enzymes, followed
by sequencing of candidates. Finally, three clones were identified
for which the corresponding codon AAA encoding lysine 460 was
mutated into codon AGA, encoding an arginine (Fig. S3). For each
KIF4A mutant (K460R) clone, an individual KIF4A control (WT)
clonewas selected which had undergone exactly the same procedure
at the same moment without introducing any mutations. To check
SUMOylation of KIF4A, these three WT and three K460R clones
were infected with lentivirus encoding His10–SUMO2 and selected
by puromycin to obtain stable cell lines. His10 pulldown and
immunoblot analysis revealed complete abolishment of KIF4A
SUMOylation in all three KIF4A K460R mutant clones, while WT
KIF4A in all three control clones was confirmed to be SUMOylated
(Fig. 4A).
Since SUMOylation can affect the subcellular localization of
target proteins, cells of each clone were plated on glass slides and
stained for endogenous KIF4A by immunofluorescence. Co-
staining against tubulin and DNA enabled recognition of cells in
various stages of mitosis. WT KIF4A was observed to localize
primarily at the midzone during anaphase and at the midbody during
cytokinesis in all three control clones (Fig. 4B; Fig. S4A). No
differences in localization were observed for K460R KIF4A in
any of the three mutant clones (Fig. 4C; Fig. S4B). Thus, the
subcellular localization of KIF4A is not regulated by SUMOylation
at position K460.
SUMOylation of endogenous KIF4A regulates abscission
While studying the samples to determine KIF4A localization
during mitosis (Fig. 5A), the relative amount of cells in mitosis
caught our attention. Indeed, upon quantification, an increased
percentage of mitotic cells was observed for each K460R mutant
clone compared to its WT control clone (Fig. S5A). The results
obtained for all three WT cell lines and the results obtained for all
three K460R cell lines were averaged (Fig. 5B). To determine
whether the increased percentage of cells in mitosis could be
attributed to a specific mitotic phase, cells were categorized into
prophase/prometaphase, metaphase, anaphase and telophase/
cytokinesis. This detailed analysis revealed an increased
percentage of cells in telophase/cytokinesis for the K460R
clones compared to their corresponding WT clones (Fig. 5C;
Fig. S5B), suggesting a role for SUMOylated KIF4A during this
final stage of cell division.
To study this phenotype in more detail, the WT and K460R
clones were transfected with GFP–tubulin and selected to create
stable cell lines (Fig. S5C). Live-cell imaging was performed using
differential interference contrast (DIC) to visualize the moment of
anaphase onset and GFP–tubulin to identify disconnection of the
intercellular MT bridge at the end of cytokinesis, which was marked
as the moment of abscission. Mitotic cells with a K460R KIF4A
background needed significantly longer (a median of 168 min) to
proceed from anaphase onset to abscission compared to cells
expressing WT KIF4A protein (a median of 114 min) (Fig. 5D;
Fig. S5D). These data indicate that the increased percentage of
cells in cytokinesis is the result of an abscission delay, uncovering
a SUMO-regulated function for KIF4A in this final step of
cell division.
Fig. 3. SUMOylation does not affect ATPase activity of KIF4A. (A) In vitro SUMOylation reactions were performed on negative control samples and
samples containing wild-type (WT) or SUMOylation-deficient (K460R and E458A/E461A) recombinant GST–KIF4A. Additional negative control assays were
carried out in the absence of SUMO2 as indicated. Subsequently, an ATPase activity assay was performed in the absence or presence of MTs and absorbance
was measured. The mean±s.d. percentage of relative ATPase activity for three independent experiments is shown. A two-sided Student’s t-test was used to
calculate P-values and the difference was considered not significant (ns) when P>0.05. (B) Aliquots of the in vitro SUMOylation samples, used for the
experiment described in Fig. 3A, were used to verify SUMOylation efficiency by immunoblotting with an antibody against KIF4A.
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SUMOylation of KIF4A enhances binding to MT destabilizer
STMN1
SUMOylation of target proteins can affect their binding to other
proteins. To determine whether SUMOylation contributes to proper
regulation of abscission through affecting binding of KIF4A to
specific partners, a mass spectrometry screen was performed
(Fig. 6A). Recombinant GST–KIF4A WT and its K460R mutant
were incubated with SUMOylation mix (Fig. S6A). As an additional
negative control, SUMO2 was omitted as indicated. Samples were
bound to beads and washed, prior to incubation with U2OS cell lysate.
After additional washing and sample preparation, peptides were
measured by mass spectrometry. Furthermore, aliquots of the protein
samples were analyzed by immunoblotting to confirm the presence of
(SUMOylated) KIF4A after incubation with the U2OS cell lysate
(Fig. S6B). Sample analysis revealed a significant preference of the
MT destabilizer stathmin 1 (STMN1) for SUMOylated WT KIF4A
compared to non-SUMOylated WT KIF4A (Fig. 6B). Differential
binding of STMN1 was also found by mass spectrometry when
comparing SUMOylated WT KIF4A with K460R KIF4A that was
incubated with the complete SUMOylation mix (Fig. 6C).
Preferential binding of recombinant GST–STMN1 to SUMOylated
KIF4Awas subsequently confirmed by immunoblotting (Fig. 6D,E).
Whereas STMN1 also binds to non-SUMOylated KIF4A,
quantification of three independent experiments confirmed
increased binding of STMN1 to SUMOylated KIF4A (Fig. 6F).
DISCUSSION
The function of SUMO, a small ubiquitin-like modifier, is
considerably less understood than that of ubiquitin itself. Here,
we studied the role of the SUMO modification of KIF4A. We
identify an important role of SUMOylated KIF4A in the regulation
of abscission as this controls the interaction with theMT destabilizer
STMN1. This is summarized in a model in Fig. 7. SUMOylation of
KIF4A increases its affinity for STMN1. Since KIF4A is a plus-
end-directed motor protein, enhanced binding of STMN1 to
SUMOylated KIF4A could affect the relative concentration of
STMN1 alongMTs, possibly enhancing its concentration at the plus-
end (Nouar et al., 2016). This could lead to local MT destabilization
to enable timely separation of daughter cells. Interestingly, no
phosphorylated peptides of this MT destabilizing protein were
identified by our mass spectrometry, indicating that SUMOylated
KIF4A interacts with the active form of STMN1 (Larsson et al.,
1997). In the absence of KIF4A SUMOylation, decreased binding of
KIF4A to STMN1 may result in slower MT destabilization, and
Fig. 4. The localization of endogenous
KIF4A during mitosis is not dependent
on SUMOylation. (A) Three KIF4A
mutant (K460R) clones and their KIF4A
wild-type (WT) control clones obtained by
CRISPR-Cas9-directed genome editing
were infected with lentivirus encoding
His10–SUMO2 and selected with
puromycin to obtain stable cell lines.
Subsequently, these cells were lysed. A
His10 pulldown was performed to enrich
for SUMOylated proteins. Input and
pulldown samples were analyzed by
immunoblotting using antibodies against
KIF4A and SUMO2/3, while Ponceau S
staining was used to confirm equal
loading. (B,C) U2OS clone 1 with (B)
endogenous KIF4A (WT) or (C) with
endogenous SUMOylation-deficient
KIF4A (K460R) were grown on glass
slides, fixed and stained with antibodies
against KIF4A (green), tubulin (red) and
Hoechst 33258 to visualize DNA (blue).
Representative images were taken of cells
in subsequent stages of mitosis to
visualize KIF4A localization. Arrows
highlight midzones and midbodies. Each
experiment was performed at least three
times. Scale bars: 10 µm.
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subsequently a delay in cytokinesis. Whereas it was previously found
that SUMO2/3, KIF4A and STMN1 are all important players in the
earlier stages of mitosis (see Introduction), our new results suggest
that these proteins team-up in a dynamic model to regulate
cytokinesis, the final step of cell division.
The SUMOylation site and SIM in KIF4A are well conserved
among higher eukaryotes, but are missing in model lower
eukaryotes such as Drosophila melanogaster and Caenorhabditis
elegans (Fig. S7). This corresponds with the absence of STMN1 in
these lower eukaryotes. Interestingly, these conservation patterns
correlate exactly with the process of open mitosis, characteristic for
higher eukaryotic cells (Güttinger et al., 2009).
Mechanistically, we report the first in vitro SUMOylation via the
inverted SUMO consensus motif (Matic et al., 2010) upon
addition of only SUMO E1 and SUMO E2, indicating that
UBC9 is able to directly recognize and modify the ExK motif. The
SIM in KIF4A is essential for its SUMOylation and most likely
responsible for the recruitment of the SUMO-charged UBC9
complex either or not employing a SUMO conjugated to UBC9
itself (Pichler et al., 2017).
To gain more insight into the effect of SUMO on KIF4A function,
we employed CRISPR-Cas9 genome editing and obtained cell lines
expressing endogenous SUMOylation-deficient mutant KIF4A. To
the best of our knowledge this is the first time this technique was
employed to study a SUMO target protein at the endogenous level,
which avoids the risks of incorrect and heterogeneous expression
levels of exogenous constructs. Moreover, it overcomes the challenge
of missing out on potential phenotypes due to partial knockdown.
Clearly, CRISPR-Cas9 genome editing should gain momentum to
reveal the functional relevance of specific post-translational
modification events in the SUMO field and beyond.
By mutating a single lysine in KIF4A, we were able to reveal a
specific function of SUMO-modified KIF4A in abscission.
Previous research using silencing techniques claimed a role of the
multifunctional KIF4A protein earlier in mitosis (Hu et al., 2011;
Kurasawa et al., 2004; Zhu and Jiang, 2005). In this case, the
function of KIF4A in abscission was missed because this stage of
mitosis is not properly reached in the absence of KIF4A. Our study
indicates that additional functions might be uncovered for other
proteins by focusing on the modification level rather than the total
Fig. 5. SUMOylation of endogenous KIF4A regulates abscission. (A) Cartoon depicting the subsequent phases of mitosis during cell division. (B) Three
independent sets consisting of a KIF4AWT and K460R clone were fixed and stained as described in Fig. 4B,C. Random images were taken and the total
amount of cells and the number of cells in mitosis per field were analyzed for at least 400 cells per clone per experiment. The percentage of cells in mitosis
was averaged for the three WT and the three K460R KIF4A clones. Mean±s.d. values are shown. ***P<0.0005 (two-sided Student’s t-test). (C) The mitotic
cells identified in the experiment described in Fig. 5B were categorized into prophase/prometaphase, metaphase, anaphase or telophase/cytokinesis. The
percentage of cells in each phase of mitosis was averaged for the three WT and the three K460R clones. Mean±s.d. values are shown. ***P<0.0005 (two-sided
Student’s t-test). Each experiment was performed at least three times. (D) All three WT and three K460R KIF4A clones were transfected with a GFP–tubulin
construct, selected using G418, subcloned and sorted by flow cytometry to obtain stable cell lines with equal GFP–tubulin expression. Live-cell imaging was
used to analyze the time from anaphase onset to abscission, based on the DIC and GFP–tubulin signal for 66 cells per WT clone and 51 cells per K460R
clone. The data obtained from the individual WT as well as the individual K460R clones were pooled and each cell is represented by a colored triangle.
Median values with interquartile ranges are shown in black. ***P<0.0005 (Mann–Whitney test).
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protein level although investigating proteins regulated by post-
translational modification at this level is challenging. Interestingly,
our results show that SUMO is able to regulate key cellular
functions by the modification of single target proteins in addition to
its role in protein group modification (Psakhye and Jentsch, 2012).
As a result of co-regulation of functional groups by SUMOylation,
phenotypes of single target proteins deficient for SUMOylation are
generally modest and quite often, no phenotypes can be found at all.
SUMOylation levels of KIF4A appeared to be rather stable
during cell cycle progression, indicating that KIF4A is continuously
Fig. 6. SUMOylation of KIF4A enhances binding to STMN1. (A) A cartoon depicting the experimental set-up to identify proteins binding preferentially to
SUMOylated KIF4A. Recombinant GST–KIF4AWT or its SUMOylation-deficient mutant (K460R) were bound to beads and in vitro SUMOylation assays
were performed. In control assays, SUMO2 was omitted. Subsequently, U2OS cell lysates were added, incubation was performed, samples were washed and
bound proteins were identified by mass spectrometry. (B) Volcano plot showing proteins binding preferentially to SUMOylated over non-SUMOylated GST–
KIF4A. On the x-axis, the Log2 fold change (FC) between the proteins identified by mass spectrometry in the samples bound to SUMOylated GST–KIF4AWT
versus non-SUMOylated GST–KIF4AWT is indicated. On the y-axis, the −Log10(P) values for the identified proteins are shown. All proteins above the dashed
line were considered significantly different between the two datasets (P<0.05). (C) Volcano plot showing proteins binding preferentially to SUMOylated
GST–KIF4AWT over the K460R mutant. The Log2FC and −Log10(P) values for the identified proteins are shown. Proteins above the dashed line were
considered significantly different between the two datasets (P<0.05). (D) Cartoon depicting the experimental procedure employed to verify STMN1 as a
differential binding protein, as identified by mass spectrometry. U2OS cells were transfected with a control or HA–KIF4AWT construct and lysed after 3 days.
Upon purification via HA IP, an in vitro SUMOylation assay was performed and in the negative control SUMO2 was omitted. Finally, the samples were
incubated with recombinant GST–STMN1, washed extensively and eluted. (E) Input and IP samples from the experiment described above were analyzed by
immunoblotting using antibodies against theHA tag andSTMN1. (F)Quantification of the result of three independent experiments presented as in Fig. 6E. Themean±s.d.
relative binding of GST–STMN1 to KIF4A is shown. *P<0.05, **P<0.005, ***P<0.0005 (two-sided Student’s t-test). Each experiment was performed at least three times.
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modified and demodified at constant rates throughout the cell cycle.
This is a fairly puzzling finding, but also intriguing and novel,
showing that a stable modification has a function at a specific phase
of mitosis (i.e. abscission). This could be due to limited
opportunities for the enzymatic machinery to carry out the
modification during cytokinesis. One thought here is that the
SUMO-conjugating machinery is equipped with DNA-binding
domains, limiting SUMO conjugation primarily to the presence of
substrates at chromatin. Therefore, the modification has to happen
prior to cytokinesis, despite its function in abscission.
In summary, we have uncovered a novel role for SUMOylated
KIF4A in cytokinesis, where it plays a role in abscission. The
process of cytokinesis is tightly regulated to ensure daughter cells
are not separated until sister chromatid segregation is completed. We
now place SUMO modification of KIF4A and the resulting
association with STMN1 in a dynamic model that is critical in the
last phase of mitosis, as shown in Fig. 7. How dynamic modification
by SUMO of KIF4A is controlled during mitosis is unclear. But
a complex SUMO-controlled event determines the final step
in mitosis.
MATERIALS AND METHODS
CRISPR-Cas9-directed genome editing
To obtain cell lines in which the triplet encoding lysine 460 in the
endogenous KIF4A was replaced by a triplet encoding arginine, CRISPR-
Cas9-directed genome editing was used in combination with a repair
template enabling targeted mutagenesis. The pSpCas9(BB)-2A-GFP
plasmid (Ran et al., 2013) was digested with BbsI (New
England Biolabs) and purified from a 1% TAE agarose gel using the
Wizard® SV Gel and PCR Clean-up System (Promega). Two guide RNA
primers were designed containing BbsI overhangs and the target
sequence upstream of the selected protospacer adjacent motif (PAM)
region close to the sequence encoding lysine 460 [forward (FW),
5′-CACCGAGTGGAGACTTTGGAAGACC-3′; and reverse (RV),
5′-AAACGGTCTTCCAAAGTCTCCACTC-3′]. These primers were
annealed and phosphorylated by T4 polynucleotide kinase (New England
Biolabs), before ligation into the BbsI digested plasmid by T4 ligase
(New England Biolabs). A repair template was designed to contain the
desired lysine to arginine mutation and several silent mutations to prevent
recognition of the repaired gene by the guide RNA and to introduce a
recognition site for the restriction enzyme TaqαI (5′-GTCATATGAATA-
ACCCTTGGGTTCTTTTTGTTTGAATTTTCAGCTGCAAACTGGATC-
TTCAAAAGCTTGTCGAGACATTGGAGGATCAGGAATTGAGAGA-
AAATGTAGAGATAATTTGTAACCTGCAGCAATTGATTACCCAGT-
TATCGGTAAGCCAAGTAGGGGCAGTGTAAAT-3′), and obtained as
4 nmole ultramer (Integrated DNATechnologies). Two million U2OS cells
were transfected with 3 µg of Cas9/GFP/guideRNA encoding plasmid
and 6 µl of 10 µM repair template using 14.4 µl Lipofectamine 2000
(Invitrogen) in Optimem (Life Technologies). At 3 days after transfection,
cells were sorted by flow cytometry and GFP-positive cells were plated at
5000 cells per 15 cm dish. Colonies were picked and maintained in 24-well
plates. DNA was purified from each clone and part of the KIF4A gene was
Fig. 7. Model of how SUMOylation of KIF4A enhances binding to MT destabilizer STMN1 and promotes abscission. Cartoon depicting the intercellular
bridge between the newly formed daughter cells during cytokinesis. (I) In cells expressing wild-type KIF4A, SUMOylation of KIF4A enhances its binding to
STMN1 at the midbody. Subsequently, MT destabilization by STMN1 is promoted, which results in abscission and thereby completion of the final step of cell
division. (II) Blocking KIF4A SUMOylation reduces STMN1 binding. Consequently, this results in reduced MT destabilization by STMN1 at the midbody and
ensuing delay in abscission.
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amplified by PCR using GoTaq polymerase (Promega) and the following
primers: FW, 5′-ACCGCCACTGATGATCTCCTG-3′ and RV, 5′-ATCA-
AATGATCCACGACCTCTGTCC-3′. The PCR product was digested by
TaqαI (New England Biolabs), to determine which cells had used the
designed template to repair the break caused by Cas9. Candidate clones and
several control clones were sequenced to confirm their identity. This
procedure was repeated until three correctly mutated clones were identified.
Each mutant clone was matched to a clone that had undergone exactly the
same procedure but was identified with a sequence encoding wild-type
(WT) KIF4A, resulting in three individual sets of a WT and a K460R clone.
Cell culture and cell lines
Unless otherwise stated, human embryonic kidney 293 (HEK293T)
cells (DuBridge et al., 1987) and human bone osteosarcoma epithelial
(U2OS) cells (ATCC) were cultured at 37°C and 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM, Thermo Fisher Scientific)
supplemented with 10% fetal bovine serum (FBS, Thermo Fisher
Scientific), 100 U/ml penicillin and 100 µg/ml streptomycin (P/S, Thermo
Fisher Scientific). Cells were authenticated and regularly tested for
mycoplasma infection and found to be negative. The U2OS cell line
stably expressing low levels of His10-tagged SUMO2 was obtained by
infection with a lentivirus encoding a His10–SUMO2 IRES GFP construct
and subsequent selection by low GFP expression as described previously
(Hendriks et al., 2014). The mature protein that is referred to as SUMO2
has the following amino acid sequence: MSEEKPKEGVKTENDHINLK-
VAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQ-
PINETDTPAQLEMEDEDTIDVFQQQTGG.
To enable enrichment of SUMOylated endogenous proteins from the
three sets of KIF4AWT and K460R clones, the cell lines were infected with
lentivirus encoding His10–SUMO2 and puromycin resistance (Hendriks and
Vertegaal, 2016b) at a multiplicity of infection (MOI) of 3 using 8 µg/ml
polybrene. Stable His10–SUMO2-expressing cell lines were created by
selection with 2.5 µM puromycin (Calbiochem). To enable visualization of
MTs by live-cell imaging, the three sets of KIF4AWT and K460R clones
were transfected with the pEGFP fused to α-tubulin plasmid (Clontech).
After selection by Geneticin (G418, Life Technologies), cells were seeded at
5000 cells per 15 cm dish. GFP-positive colonies were picked based on
equal expression levels and additionally sorted by flow cytometry.
Site-directed mutagenesis
Mutations were introduced in the WT KIF4A construct encoding the
canonical KIF4A protein (Uniprot identifier O95239-1) using QuikChange
site-directed mutagenesis (Stratagene). The forward and reverse primers
used were: K460R, FW, 5′-GACCAGGAATTGAGAGAAAATGTAGAG-
3′, RV, 5′-CTCTACATTTTCTCTCAATTCCTGGTC-3′; E458A, FW,
5′-GTGGAGACTTTGGAAGACCAGGCGTTGAAAGAAAATGTAGAG-
3′, RV 5′-CTCTACATTTTCTTTCAACGCCTGGTCTTCCAAAGTCTC-
CAC-3′; E461A, FW, 5′-GGAAGACCAGGAATTGAAAGCGAATGT-
AGAGATAATTTG-3′, RV, 5′-CAAATTATCTCTACATTCGCTTT-
CAATTCCTGGTCTTCC-3′; E458A/E461A, FW, 5′-CTTTGGAAGA-
CCAGGCGTTGAAAGCGAATGTAGAG-3′, RV, 5′-CTCTACATTCG-
CTTTCAACGCCTGGTCTTCCAAAG-3′; ΔSIM FW, 5-CTGAAAGTG-
TCTTACTTAGAGATTTACAATGAAGAAGCTGCGGATGCTGCAT-
GCCCATCTCGTGAGAAAGC-3′, RV 5′-GCTTTCTCACGAGATG-
GGCATGCAGCATCCGCAGCTTCTTCATTGTAAATCTCTAAGTAA-
GACACTTTCAG-3′.
Transfection and lentivirus production
Cells were plated in FBS-containing DMEM without P/S. To overexpress
the indicated protein, U2OS cells were transfected with 24 µg plasmid DNA
and 60 µg polyethylaneimine (PEI) at 60% confluency in a 15 cm dish.
Medium was replaced for DMEM containing FBS and P/S after 24 h, and
cells were washed with PBS and lysed 3 days after transfection to obtain
total lysate samples (input) and samples for protein purification (His10
pulldown or HA immunoprecipitation) unless otherwise stated. To produce
lentivirus, HEK293T cells were transfected with 7.5 µg pCMV-VSVG,
11.4 µg pMDLg-RRE, 5.4 µg pRSV-REV and 13.7 µg of a plasmid
encoding SUMO2 as well as puromycin resistance. The medium was
collected 48 and 72 h after transfection and filtered using a 0.45 µm syringe
filter (Pall Life Science). The virus titer was determined using p24 ELISA
and the sample was stored at −20°C until use.
His10 pulldown
Enrichment of SUMOylated proteins was performed by His10 pulldown as
described previously (Hendriks et al., 2014). In short, cells were
resuspended in lysis buffer, sonicated and equalized using BCA Protein
Assay Reagent (Thermo Fisher Scientific). Lysates were incubated with
Ni-NTA beads (Qiagen) overnight at 4°C, washed and eluted for 30 min
at room temperature (RT).
HA immunoprecipitation
To detect modification of exogenous HA-tagged KIF4A with endogenous
SUMO2/3, an HA immunoprecipitation (IP) was performed to preserve
SUMOylation on target proteins according to the following protocol. Cells
were lysed in buffer 1, containing 1% SDS, 0.5% NP-40, 50 mM NaF,
1 mMNaVO3, 5 mM β-glycerol phosphate, 5 mM sodium pyruvate (NaPy),
0.5 mM EGTA, 5 mM PNT, protease inhibitors with EDTA, 70 mM
chloroacetamide (CAA) and 1× PBS. Samples were equalized using BCA
Protein Assay Reagent and diluted with an equal volume of buffer 2 (2%
Triton X-100, 0.5% sodium deoxycholate, 1% BSA, 5 mM NaF, 1 mM
NaVO3, 5 mM β-glycerol phosphate, 5 mM NaPy, 0.5 mM EGTA, 5 mM
PNT, protease inhibitors with EDTA, 70 mM CAA and 1× PBS). Upon
centrifugation at 4°C and 13,200 rpm (15,000 g) for 45 min, the supernatant
was collected and incubated with EZview red anti-HA affinity gel (Sigma)
for 90 min at 4°C while rotating. Samples were washed four times with
buffer 3, containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40,
5 mM NaF, 1 mM NaVO3, 5 mM β-glycerol phosphate, 5 mM NaPy,
0.5 mM EGTA, 5 mM PNT, protease inhibitors with EDTA and 70 mM
CAA. Next, samples were washed twice with buffer 4, containing 50 mM
Tris-HCl pH 7.5, 150 mM NaCl and 0.5% NP-40. Finally, samples were
eluted for 30 min at RT and 1200 rpm (500 g) in buffer 4 supplemented with
100 µg/ml HA-peptide (Sigma).
To purify HA-tagged KIF4A for in vitro SUMOylation reactions, an HA
IP was performed in a non-denaturing manner according to the following
protocol. Cells were lysed in buffer 5, containing 30 mM HEPES pH 7.6,
130 mM NaCl, 1 mM MgCl2, 0.5% Triton X-100, protease inhibitors with
EDTA and 70 mM CAA. Samples were incubated on ice for 10 min, before
centrifugation at 4°C and 15,000 g for 10 min. The supernatant was
collected and equalized using BCA Protein Assay Reagent. After incubation
with EZview red anti-HA affinity gel for 90 min at 4°C while rotating,
samples were washed six times in buffer 5. Finally, samples were eluted
in buffer 5 supplemented with 100 µg/ml HA-peptide at RT and 1200 rpm
(500 g) for 30 min.
SUMOylation of eluted HA–KIF4A
HA–KIF4A enriched from 4×106 U2OS cells by HA-IP as described above
was in vitro SUMOylated. Unless otherwise stated, samples were incubated
in a total volume of 20 µl for 3 h at 4°C with SUMOylation mix, containing
50 mM Tris-HCl pH 7.5, 5 mM MgCl2, 3.5 U/ml creatine kinase, 10 mM
creatine phosphate, 1.1 U/ml inorganic pyrophosphatase, 2 mM ATP,
600 ng SUMO E1, 2 µg SUMO E2 and 4.4 µg SUMO2 Kzero (K0)
(made in-house). SUMO2 K0 refers to a mutant SUMO2 in which all lysine
residues were mutated into arginine residues to prevent SUMO chain
formation.
Electrophoresis, immunoblotting and antibodies
For each experiment, the collected cells were divided in at least two aliquots,
including one for total lysate samples (input) and one for protein purification
(His10 pulldown or HA IP). Inputs were lysed in input buffer (1% SDS, 1%
NP-40, 50 mM Tris-HCl pH 7.5 and 150 mM NaCl), incubated at 99°C for
10 min at 1200 rpm (500 g) and equalized using BCA Protein Assay
Reagent, followed by immunoblot analysis. Purification samples were
prepared according to the His10 pulldown or HA IP protocol. For
immunoblot analysis, dithiothreitol (DTT, Sigma) and NuPAGE LDS
Sample Buffer (LDS, Life Technologies) were added, and each sample was
incubated at 70°C for 10 min. Proteins were separated by gel electrophoresis
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on 8% or 15% gels made in-house in Tris-glycine buffer for 75 min at
150 V. Proteins were transferred to Hybond nitrocellulose membranes (GE
Healthcare) in cold transfer buffer at 25 V for 3 h. Subsequently, proteins
were stained with Ponceau S (Sigma) to confirm equal loading and
membranes were blocked in PBS with 0.05% Tween-20 (Merck) (PBS/T)
and 8% milk powder (blocking solution) for 1 h at RT. Membranes were
incubated overnight at 4°C with primary antibodies diluted in blocking
solution, including rabbit polyclonal anti-KIF4A (Bethyl, A301-074A,
1:2000), mouse monoclonal anti-SUMO2/3 (Abcam, 8A2, 1:2000), mouse
monoclonal anti-HA.11 (Sanbio, MMS-101R, 1:1000), mouse monoclonal
anti-α-tubulin (Sigma, T6199, 1:1000), rabbit polyclonal anti-GFP (Novus
Biologicals, NB600-308, 1:1000) and rabbit monoclonal anti-STMN1 (Cell
Signaling Technology, D1Y5A, 1:1000). Membranes were washed three
times for 10 min at RT in PBS/T, before incubation with HRP-coupled
secondary donkey anti-rabbit-IgG or goat anti-mouse-IgG antibodies
(Pierce) diluted in blocking solution for 1 h at 4°C. Upon washing in
PBS/T three times for 10 min at 4°C, Pierce ECL 2 immunoblotting
substrate (Life Technologies) was used to visualize the signal on RX
Medical films (Fuji).
Cell synchronization and fluorescence-activated cell sorting
analysis
Two blocking agents were used to synchronize cells into specific cell cycle
stages. Thymidine (Sigma) was added at a concentration of 4 mM to block
cells at the border of G1 to S phase. After 16 h, cells were lysed immediately
(G1 phase) or washed twice with PBS to release them from their cell cycle
arrest. These cells were either released into DMEMwith FBS and P/S for 5 h
(early S phase) or 8 h (late S phase) or into DMEM with FBS, P/S and
0.1 µg/ml nocodazole (Sigma) to block cells in prometaphase. After 20 h,
these arrested cells were lysed immediately (early M phase) or released into
DMEMwith FBS and P/S for 30 min (midM phase), 2 h (late M phase), 4 h
(G1 phase) or 8 h (G1/S phase). Cells were collected using trypsin treatment
and washed with PBS. Finally, each sample was divided into three aliquots,
which were fixed for fluorescence-activated cell sorting (FACS) analysis,
lysed to perform a His10 pulldown or lysed to obtain input samples.
The samples harvested for FACS analysis were fixed in 70% ice-cold
ethanol and incubated at 4°C for at least 16 h. Samples were prepared on the
day of measurement by flow cytometry, starting with centrifugation at
1200 rpm (500 g) for 2 min and washing in PBS with 2% FBS. Upon a
second centrifugation step, cells were resuspended in PBS containing 2%
FBS, 25 µg/ml propidium iodide (Sigma) and 100 µg/ml RNase A (Sigma).
Samples were stained for 30 min at 37°C, followed by measuring the
cellular DNA content by flow cytometry with the BD LSRII system and BD
FACS DIVA software (BD Bioscience Clontech).
ATPase activity assay
Recombinant GST–KIF4A wild-type (WT) or SUMO deficient mutants
(K460R and E458A/E461A) were in vitro SUMOylated by incubation at 4°C
for 3 h. The complete SUMOylation mix used for one ATPase activity
reaction contained 2.5 µg GST–KIF4A, 750 ng SUMOE1, 2.5 µg SUMOE2
and 5.5 µg SUMO2 K0 in 50 mM Tris-HCl pH 7.5, 5 mMMgCl2 and 2 mM
ATP (dissolved in PIPES). As a non-SUMOylated control, the same reaction
was performed but omitting SUMO2 K0. Aliquots of all SUMOylation
reactions were saved for immunoblot analysis. To measure ATPase activity
the Kinesin ATPase end-point assay (Cytoskeleton) was used according to the
manufacturer’s instructions, except for the use of 300 µl wells and therefore
doubling all reaction volumes. As an additional control, all experimental
conditions were also incubated in the absence of MTs to determine
background activity. Absorbance was measured at 650 nm with a Synergy
HT spectrophotometer (BioTek). Three independent experiments were
performed and average relative absorbance with standard deviations were
calculated. A two-sided Student’s t-test was used to determine P-values.
Immunofluorescence
All three sets ofWT and K460RKIF4A clones were plated on glass slides in
24-well plates. After 2 days, cells were fixed for 15 min at RT in 4% PFA
and washed four times in PBS. Cells were permeabilized with 1% Triton X-
100 in PBS for 15 min at RT, followed by washing twice with PBS and once
with PBS/T. Samples were blocked for 10 min in TNB, containing 100 mM
Tris-HCl pH 7.5, 150 mM NaCl and 0.5% blocking reagent (Roche).
After incubation for 1 h at RT with primary antibodies against KIF4A and
tubulin diluted in TNB, coverslips were washed five times with PBS/T.
Then, cells were incubated for 1 h at RT with secondary antibodies (Alexa-
Fluor-488-conjugated goat anti-mouse-IgG and Alexa-Fluor-594 goat anti-
rabbit-IgG) diluted in TNB and washed five time with PBS/T. Coverslips
were dehydrated by incubating for 1 min each with 70%, 90% and 100%
ethanol. Finally, coverslips were mounted onto a microscopy slide using
ProLong Gold (Life Technologies) containing 5 µg/ml Hoechst 33258 (Life
Technologies).
For high-resolution images, mitotic cells were visualized using a Leica
TCS SP8 confocal microscope with a 63× objective. Z-stacks were made of
cells from top to bottom with 0.4 µm steps at a 1024×1024 format with a
speed of 100 Hz. Finally, maximum projections were made and shown in
the figures. To determine the percentage of mitotic cells, random images
were taken on a Leica DM6B fluorescence microscope. The numbers of
total cells and of mitotic cells were analyzed per image for at least 400 cells
per clone per experiment. The percentage of cells in mitosis and in each
subphase was calculated for six independent experiments and averaged for
each clone. The means with standard deviations are shown in the
supplementary figures. The results for the three WT and three K460R cell
lines were averaged, for which the data with standard deviations are
shown in the main figures. A two-sided Student’s t-test was used to calculate
P-values.
Live-cell imaging
Cells were grown on glass-bottomed CG imaging chambers (Zell-Kontakt)
in DMEM supplemented with FBS and P/S at 37°C in a humidified
atmosphere containing 5% CO2. Before imaging, the medium was changed
to Phenol Red-free CO2-independent Leibovitz’s L-15 medium (Thermo
Fisher Scientific) supplemented with FBS, and the lid was exchanged for a
DIC lid (Zell-Kontakt). Movies were acquired using the Eclipse Ti wide-
field microscope (Nikon) with a Plan Apo λ 60× NA 1.4 objective at 37°C in
an environment chamber. Five optical sections were collected every 1.5 µm
using the ORCA-Flash 4.0 CMOS camera C11440-22CU (Hamamatsu);
2×2 binning was applied for increased signal intensity.
To determine timing from anaphase onset to abscission, mitotic
progression of 66 cells per WT clone and of 51 cells per K460R clone
was analyzed using Image J software version 1.50e. Anaphase onset was
determined as the first frame in which the start of chromosome segregation
was visible by DIC. These cells were followed while continuing mitosis
until the intercellular MT bridge was disconnected at the end of cytokinesis,
and this frame was marked as the moment of abscission. The timing from
anaphase onset to abscission for each individual cell is represented by a
colored triangle, while the medians with interquartile ranges are shown in
black. The results for the individual clones are shown in the supplementary
figure, while the main figure shows all 198 WT and 153 K460R cells
analyzed from the individual clones pooled together. A Mann–Whitney test
was used to calculate P-values.
Identification of GST–KIF4A-binding proteins by mass
spectrometry and data analysis
An in vitro SUMOylation reaction was performed for 3 h at 4°C with 10 µg
recombinant WT or K460R GST–KIF4A in buffer containing 50 mM Tris-
HCl pH 7.5, 5 mM MgCl2, 2 mM ATP, 3 µg SUMO E1, 10 µg SUMO E2
and 20 µg SUMOK0. The same buffer conditions, except for the absence of
SUMO K0, were used as an additional negative control. Samples were
incubated with glutathione–Sepharose 4 Fast Flow beads (GE Healthcare)
for 1 h at 4°C, followed by washing twice with buffer 6 (50 mM Tris-HCl
pH 7.5, and 150 mM NaCl). Subsequently, samples were incubated for 2 h
at 4°C with U2OS cell lysate. Lysates were prepared in buffer containing
50 mM Tris-HCl pH 7.5, 150 mMNaCl, 0.5% Triton X-100 and 10 mMN-
ethylmaleimide (NEM, Sigma) and protease inhibitors with EDTA. After
washing three times with buffer 6, samples were washed three times with
50 mM ammonium bicarbonate (ABC, Sigma) and eluted for 30 min at RT
and 1200 rpm (500 g) in ABC complemented with 20 mM glutathione
(Sigma).
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Samples were passed through pre-washed 0.45 µm filter columns to
remove the beads and digested by incubation with 2 µg trypsin (Promega)
overnight at 37°C while shaking at 500 rpm. To acidify the samples,
trifluoroacetic acid (TFA, Sigma) was added to a final concentration of 2%.
Stage tips containing C18 (Sigma) were activated by passing HPLC-grade
methanol (Sigma), washed with 80% acetonitrile (ACN, Sigma) in 0.1%
formic acid (FA, Sigma) and equilibrated with 0.1% FA. Samples were
loaded on these stage tips, washed twicewith 0.1% FA and eluted twicewith
80% ACN. Finally, samples were vacuum dried using a SpeedVac RC10.10
(Jouan), redissolved in 0.1% FA and transferred to autoloader vials before
measurement by mass spectrometry. Four independent experiments were
performed and all samples were measured by nanoflow liquid
chromatography-tandem mass spectrometry (nanoLC-MS/MS) on an
EASY-nLC 1000 system (Proxeon) connected to an Orbitrap Q-Exactive
(Thermo Fisher Scientific) through a nano-electrospray ion source. Raw
data analysis was performed using Max Quant Software version 1.5.3.30
with its integrated search engine Andromeda. The search was performed
against the in silico digested proteome containing 92,180 entries of Homo
sapiens from UniProt (24th March 2016). Label-free quantification was
performed using LFQ settings with fast LFQ disabled to quantify all
identified peptides (Tables S1 and S2). Proteins identified by the same set
of peptides were combined to a single protein group by Max Quant
(Tables S1 and S3). These protein groups were further analyzed using
Perseus Software version 1.5.2.4. Proteins identified in the categories
‘potential contaminant’, ‘reverse’ or ‘only identified by site’ were removed.
The LFQ intensities were log2 transformed and the experimental replicates
for each condition were assigned together in an experimental group.
Subsequently, all proteins that were not identified in each experimental
replicate of at least one experimental group were removed. Missing values
were imputed based on the total matrix, using normally distributed values
with a randomized 0.3 width (log2) and a 1.8 down shift (log2). Two-sided
Student’s t-tests were performed between the indicated samples to obtain
P-values and differences for each protein. These values were visualized in a
volcano plot, showing P-values [as −Log10(P)] on the y-axis and
differences [as Log2FC (fold change)] on the x-axis. All proteins with a
P<0.05 were considered to bind significantly differently between the two
indicated experimental groups (Tables S1 and S4).
GST–STMN1 binding to HA–KIF4A
At 3 days after transfection of U2OS cells with control or HA–KIF4AWT
plasmid, cells were lysed in buffer 7 (50 mM Tris-HCl pH 7.5, 5 mM
MgCl2, 150 mM NaCl and 0.5% Triton X-100). Samples were sonicated
and centrifuged at 15,000 g for 30 min at 4°C. Upon collection of the
supernatant, BCA Protein Assay Reagent was used to equalize the
samples. Then, samples were incubated with EZview red anti-HA affinity
gel for 90 min at 4°C and washed twice in buffer 7. Upon washing twice in
buffer 8 (50 mM Tris-HCl pH 7.5 and 5 mM MgCl2), an in vitro
SUMOylation reaction was performed on the beads containing
HA–KIF4A enriched from 106 U2OS cells for 3 h at 4°C with rotation
in a total reaction volume of 50 µl containing 50 mM Tris-HCl pH 7.5,
5 mM MgCl2, 4 mM ATP, 1.5 µg SUMO E1, 5 µg SUMO E2 and 10 µg
SUMO K0. Samples were washed three times with buffer 6, followed by
incubation with 1 µg recombinant GST–STMN1 WT for 2 h at 4°C with
rotation. Finally, samples were washed in buffer 7 and eluted in buffer 7
supplemented with 100 µg/ml HA-peptide at RT and 1200 rpm (500 g) for
30 min. After performing electrophoresis and immunoblotting as described
above, the obtained signal was quantified using Fiji version 2.0.0. Three
independent experiments were performed and average relative binding with
standard deviations were calculated. A two-sided Student’s t-test was used to
determine P-values.
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Figure S1 SUMOylation of endogenous KIF4A is stable during cell cycle progression. (A) 
Overview of the cell cycle synchronization strategy indicates the treatment, time of 
incubation and time of release to obtain cells in the indicated cell cycle phase. (B) U2OS cells 
without or with stable expression of his10-SUMO2 were synchronized at the indicated cell 
cycle phases using thymidine and nocodazole. Cells were lysed and his10-pulldowns 
were performed to enrich for SUMOylated proteins. Samples were analyzed by 
immunoblotting using antibodies against KIF4A and SUMO2/3. (C) Cell cycle synchronization 
described in Supplementary information, Figure 1B was confirmed by flow cytometry. Each 
experiment was performed at least three times. 
J. Cell Sci.: doi:10.1242/jcs.248591: Supplementary information
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Figure S2 SUMOylation of endogenous KIF4A is stable during mitotic progression. (A) 
Overview of the cell cycle synchronization strategy indicates the treatment, time of 
incubation and time of release to obtain cells in the indicated mitotic phase. (B) U2OS cells 
without or with stable expression of his10-SUMO2 were synchronized in mitosis as indicated 
using thymidine and nocodazole. Cells were lysed and his10-pulldowns were performed 
to enrich for SUMOylated proteins. Input and pulldown samples were analyzed by 
immunoblotting using antibodies against KIF4A and SUMO2/3. (C) Mitotic cell cycle 
synchronization described in Supplementary information, Figure 2B was confirmed by flow 
cytometry. Each experiment was performed at least three times. 
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Figure S3 CRISPR-Cas9-directed genome editing was used in combination with a repair 
template for targeted mutation of the KIF4A gene, resulting in a replacement of the 
endogenous lysine 460 with an arginine in the KIF4A protein. After subcloning, 
genome editing was verified by PCR amplification and diagnostic digestion. 
Subsequently, sequencing was performed to confirm either wildtype (WT) or mutant (K460R) 
KIF4A identity.  
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Figure S4 The localization of endogenous KIF4A during mitosis is not dependent on 
SUMOylation. (A) Two additional U2OS cell lines expressing endogenous WT KIF4A (clone 2 
and 3) or (B) endogenous K460R KIF4A (clone 2 and 3) were grown on glass slides, fixed 
and stained with antibodies against KIF4A (green), tubulin (red) and Hoechst to visualize 
DNA (blue). Representative images were taken of cells in different stages of mitosis to visualize 
KIF4A localization. Scale bars correspond to 10 µm. Each experiment was performed at least 
three times. 
J. Cell Sci.: doi:10.1242/jcs.248591: Supplementary information
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Figure S5 Increased mitotic index and delay in abscission in cells deficient for SUMOylation of 
endogenous KIF4A. (A) Three independent sets (1, 2 and 3) of KIF4A wildtype (WT) and 
SUMOylation deficient (K460R) clones were fixed and stained with Hoechst and antibodies 
directed against KIF4A and tubulin. Images were taken randomly and analyzed for the total 
amount of cells and the number of cells in mitosis. The mean percentage of cells in mitosis 
for each set of KIF4A WT and K460R clones is shown with corresponding standard 
deviations. P values were calculated using a two-sided Student T-test. One star 
represents p < 0.05 and two stars p < 0.005. ns, not significant. (B) The mitotic cells identified in 
the experiment described in Supplementary information, Figure 5A were categorized into 
prophase/prometaphase, metaphase, anaphase or telophase/cytokinesis. The mean percentage 
of cells in each phase of mitosis for each set of KIF4A WT and K460R clones is shown with 
corresponding standard deviations. P values were calculated using a two-sided Student T-test. 
One star represents p < 0.05, two stars p < 0.005 and three stars p < 0.0005. Each experiment 
was performed at least three times. (C) All three WT and three K460R KIF4A clones were 
transfected with a GFP-tubulin construct, selected using G418, subcloned and sorted by flow 
cytometry to obtain stable cell lines with equal GFP-tubulin expression. Cells were lysed and 
samples were analyzed by immunoblotting using an antibody against GFP. (D) Live cell imaging 
was used to analyze the time from anaphase onset to abscission, based on the DIC and GFP-
tubulin signal for 66 cells per WT clone and 51 cells per K460R clone. Each individual cell is 
represented by a colored triangle, while the medians with interquartile ranges are shown in black 
for each set of WT and K460R clone. P values were calculated using the Mann Whitney test. 
One star represents p < 0.05 and three stars p < 0.0005.  
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250 kDa -
148 kDa -
SUMO2: - +
GST-KIF4A: WT
anti-KIF4A
- +
K460R
250 kDa -
148 kDa -
SUMO2: - +
anti-KIF4A
- +
GST-KIF4A: WT K460R
Figure S6 Confirmation of in vitro SUMOylation KIF4A before and after lysate incubation. (A) 
Recombinant GST-KIF4A wildtype (WT) or SUMOylation deficient mutant (K460R) were 
bound to beads and an in vitro SUMOylation assay was performed in the absence or 
presence of SUMO2. Aliquots of the samples were used to verify SUMOylation efficiency 
by immunoblotting using an antibody against KIF4A. (B) The samples described in 
Supplementary information, Figure 6A were incubated with a U2OS lysate and washed. Prior to 
sample preparation for mass spectrometry analysis, aliquots of the samples were saved to verify 
SUMOylation and protein levels by immunoblotting using an antibody against KIF4A. Each 
experiment was performed at least three times.  
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B KIF4A 1 460 1232
 E x K E 
A
KIF4A AA 1-1232
Nucleotide binding AA 88-95
Motor domain AA 9-336
PRC1 interaction domain AA 663-1232
Globular region AA 1000-1232
Coiled-coil region AA 350-999
Nuclear localization signal AA 793-798
C KIF4A 1 148-152 1232
I L D L L
Homo sapiens 428 EKMNAKLEELRQ-------HAACKLDL-QKLVETLEDQELKENVEIICNL 469 
Canis lupus familiaris 429 EKMNAKLEELRQ-------HAALKVDL-QKLVETLEDQELKENVEIIRNL 470
Bos taurus 429 EKMNAKLEELRK-------HAACKVDL-QKLVETLEDQELKENVEIIRNL 470
Mus musculus 429 EKMNAKLEELRR-------HAACKVDL-QKLVETLEDQELKENIEIICNL 470
Rattus norvegicus 429 EKMNAKLEELRQ-------HAACKVDL-QKLAETLEDQEVKENIEIICNL 470
Gallus gallus 431 EKMNAKLEQLQQ-------HAVCKLDL-QKLLETVEDEELKENVEVIRNL 472
Xenopus (Silurana) tropicalis 429 EKLASKIEELKQ-------HAACKVDL-QRLVETLEDQELKENVGVILDL 470
Drosophila melanogaster 445 DKLRSHVSELKN-------KLDQREQAQFGNENTNGDNEMRDFSLLVNRV 487
Caenorhabditis elegans 416 SRLEEDKAKLQS--------------MLTDVRNTVLNEEMLDAAEVVRSI 451
Arabidopsis thaliana 445 DKLIMIIESVRNGKSLDEIESCQNEDVGLVNKYVSKIQELEGELLHIKNL 494
Homo sapiens 139 SYLEIYNEEILDLLCPSRE--------------K--A-QINIREDPKEGI 171 
Canis lupus familiaris 139 SYLEIYNEEILDLLCPSRE--------------K--ASQINIREDPKEGI 172 
Bos taurus 139 SYLEIYNEEILDLLCPSRE--------------K--APQINIREDPKEGI 172 
Mus musculus 139 SYLEIYNEEILDLLCSSRE--------------K--ATQINIREDPKEGI 172 
Rattus norvegicus 139 SYLEIYNEEILDLLCSSRE--------------K--ASQINIREDPKEGI 172 
Gallus gallus 139 SYLEIYNEDILDLLCSSRE--------------R--SSQISIREDPKEGI 172
Xenopus (Silurana) tropicalis 138 SYLEIYNEEILDLLYAARD--------------K--TNAISIREDPKEGI 171 
Drosophila melanogaster 138 SFVELYQEQFYDLFSSKTR--------------D--KATVDIRE-VKNRI 170
Caenorhabditis elegans 136 SMFEVYGDNVYDLLRPDKV-------------------KLNVHGDEKN-C 165 
Arabidopsis thaliana 134 SFIEIFKEEVFDLLDSNSSALLKNDSGVQAKHTALSRAPIQIRETASGGI 183 
Figure S7 KIF4A SUMOylation site and SUMO interaction motif conservation. (A) A cartoon 
depicting the localization of known domains and regions in the KIF4A protein. AA, amino 
acid. (B) Cartoon showing the localization of the SUMOylation site, containing lysine 460, in 
the KIF4A protein and the conservation of this region across the indicated species. (C) 
Cartoon depicting the localization of the SUMO interaction motif (SIM) in the KIF4A protein 
and the conservation of this region across the indicated species.  
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Table S1 Key of sample names. This sheet explains which sample name belongs to each 
exact sample measured.  
Table S2 A list of all peptides identified by Max Quant on the RAW Peptides sheet.  
Table S3 A list of all protein groups for which peptides were identified by Max Quant on 
the RAW ProteinGroups sheet.  
Table S4 A list of proteins for which their binding to KIF4A is significantly affected by 
SUMOylation. The line separates proteins that were identified to preferentially bind 
SUMOylated KIF4A (top) from the proteins that favoured binding to non-SUMOylated 
KIF4A (bottom).  
Click here to Download Table S1
Click here to Download Table S2
Click here to Download Table S3
Click here to Download Table S4
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